Radio-opaque Contrast Agents for Liver Cancer Treatment
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Recruiting
Observational Study
Liver Neoplasm
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- University of Sydney · Other
Who this trial is looking for
This trial is looking for liver cancer patients who receive specific types of radiation therapy. Participants will have imaging tests to see if contrast agents used in their treatment can be tracked by software during their radiation sessions.
Are You a Good Fit for This Trial?
You may be able to join if
- I am receiving stereotactic ablative body radiotherapy (SABR) for liver cancer.
- I have received a radio-opaque contrast agent that shows up on CT scans.
- The contrast agent is within the x-ray imaging view during my scans.
- I can provide written consent to participate.
You may not be able to join if
- I am less than 18 years old.
- I do not have the required image data for the trial.
- My image data is not in a compatible format.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detect…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.
* Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan
* The radio-opaque…
Contacts